- Home
- IVT vs ARQT Comparison
IVT vs ARQT Comparison
Compare IVT & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVT
- ARQT
- Stock Information
- Founded
- IVT 2005
- ARQT 2016
- Country
- IVT United States
- ARQT United States
- Employees
- IVT N/A
- ARQT N/A
- Industry
- IVT Real Estate Investment Trusts
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- IVT Real Estate
- ARQT Health Care
- Exchange
- IVT Nasdaq
- ARQT Nasdaq
- Market Cap
- IVT 2.3B
- ARQT 2.1B
- IPO Year
- IVT N/A
- ARQT 2020
- Fundamental
- Price
- IVT $28.56
- ARQT $20.72
- Analyst Decision
- IVT Hold
- ARQT Strong Buy
- Analyst Count
- IVT 5
- ARQT 7
- Target Price
- IVT $32.00
- ARQT $19.00
- AVG Volume (30 Days)
- IVT 543.8K
- ARQT 2.0M
- Earning Date
- IVT 10-28-2025
- ARQT 10-28-2025
- Dividend Yield
- IVT 3.40%
- ARQT N/A
- EPS Growth
- IVT 1533.99
- ARQT N/A
- EPS
- IVT 1.47
- ARQT N/A
- Revenue
- IVT $287,075,000.00
- ARQT $263,464,999.00
- Revenue This Year
- IVT $9.70
- ARQT $72.46
- Revenue Next Year
- IVT $8.25
- ARQT $31.69
- P/E Ratio
- IVT $18.99
- ARQT N/A
- Revenue Growth
- IVT 9.17
- ARQT 99.50
- 52 Week Low
- IVT $25.21
- ARQT $8.03
- 52 Week High
- IVT $31.65
- ARQT $21.84
- Technical
- Relative Strength Index (RSI)
- IVT 53.91
- ARQT 59.51
- Support Level
- IVT $27.54
- ARQT $20.34
- Resistance Level
- IVT $28.22
- ARQT $21.20
- Average True Range (ATR)
- IVT 0.51
- ARQT 1.02
- MACD
- IVT 0.09
- ARQT -0.07
- Stochastic Oscillator
- IVT 89.57
- ARQT 57.49
About IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.